Physiologically Based Pharmacokinetics Modeling and Transporter Proteomics to Predict Systemic and Local Liver and Muscle Disposition of Statins

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2024 Apr 5

PMID 38576225

Authors

Luna Prieto Garcia

Anna Vildhede

Par Nordell

Christine Ahlstrom

Ahmed B Montaser

Tetsuya Terasaki

Hans Lennernas

Erik Sjogren

Affiliations

Soon will be listed here.

Abstract

Statins are used to reduce liver cholesterol levels but also carry a dose-related risk of skeletal muscle toxicity. Concentrations of statins in plasma are often used to assess efficacy and safety, but because statins are substrates of membrane transporters that are present in diverse tissues, local differences in intracellular tissue concentrations cannot be ruled out. Thus, plasma concentration may not be an adequate indicator of efficacy and toxicity. To bridge this gap, we used physiologically based pharmacokinetic (PBPK) modeling to predict intracellular concentrations of statins. Quantitative data on transporter clearance were scaled from in vitro to in vivo conditions by integrating targeted proteomics and transporter kinetics data. The developed PBPK models, informed by proteomics, suggested that organic anion-transporting polypeptide 2B1 (OATP2B1) and multidrug resistance-associated protein 1 (MRP1) play a pivotal role in the distribution of statins in muscle. Using these PBPK models, we were able to predict the impact of alterations in transporter function due to genotype or drug-drug interactions on statin systemic concentrations and exposure in liver and muscle. These results underscore the potential of proteomics-guided PBPK modeling to scale transporter clearance from in vitro data to real-world implications. It is important to evaluate the role of drug transporters when predicting tissue exposure associated with on- and off-target effects.

Citing Articles

Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins.

Prieto Garcia L, Vildhede A, Nordell P, Ahlstrom C, Montaser A, Terasaki T CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):1029-1043.

PMID: 38576225 PMC: 11179708. DOI: 10.1002/psp4.13139.

References

Pedersen J, Matsson P, Bergstrom C, Norinder U, Hoogstraate J, Artursson P . Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem. 2008; 51(11):3275-87. DOI: 10.1021/jm7015683. View

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

Badee J, Achour B, Rostami-Hodjegan A, Galetin A . Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. Drug Metab Dispos. 2015; 43(4):424-32. DOI: 10.1124/dmd.114.062034. View

Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F . SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008; 359(8):789-99. DOI: 10.1056/NEJMoa0801936. View

Stride B, Grant C, Loe D, Hipfner D, Cole S, Deeley R . Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997; 52(3):344-53. DOI: 10.1124/mol.52.3.344. View

Prieto Garcia L, Lundahl A, Ahlstrom C, Vildhede A, Lennernas H, Sjogren E . Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction. CPT Pharmacometrics Syst Pharmacol. 2022; 11(9):1194-1209. PMC: 9469690. DOI: 10.1002/psp4.12837. View

Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund H, Schafmayer C . A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol. 2013; 1:e13. PMC: 3600730. DOI: 10.1038/psp.2012.14. View

Varma M, Rotter C, Chupka J, Whalen K, Duignan D, Feng B . pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011; 8(4):1303-13. DOI: 10.1021/mp200103h. View

Medwid S, Li M, Knauer M, Lin K, Mansell S, Schmerk C . Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metab Dispos. 2019; 47(8):832-842. DOI: 10.1124/dmd.119.087619. View

10.

Pasanen M, Neuvonen M, Neuvonen P, Niemi M . SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006; 16(12):873-9. DOI: 10.1097/01.fpc.0000230416.82349.90. View

11.

Jacobson T . Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006; 97(8A):44C-51C. DOI: 10.1016/j.amjcard.2005.12.009. View

12.

Bosgra S, van de Steeg E, Vlaming M, Verhoeckx K, Huisman M, Verwei M . Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. Eur J Pharm Sci. 2014; 65:156-66. DOI: 10.1016/j.ejps.2014.09.007. View

13.

Akanuma S, Uchida Y, Ohtsuki S, Kamiie J, Tachikawa M, Terasaki T . Molecular-weight-dependent, anionic-substrate-preferential transport of β-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet. 2011; 26(6):602-11. DOI: 10.2133/dmpk.DMPK-11-RG-063. View

14.

Prieto Garcia L, Vildhede A, Nordell P, Ahlstrom C, Montaser A, Terasaki T . Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):1029-1043. PMC: 11179708. DOI: 10.1002/psp4.13139. View

15.

Afrouzian M, Al-Lahham R, Patrikeeva S, Xu M, Fokina V, Fischer W . Role of the efflux transporters BCRP and MRP1 in human placental bio-disposition of pravastatin. Biochem Pharmacol. 2018; 156:467-478. PMC: 6502225. DOI: 10.1016/j.bcp.2018.09.012. View

16.

Yamazaki M, Akiyama S, Niinuma K, Nishigaki R, Sugiyama Y . Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997; 25(10):1123-9. View

17.

Schirris T, Renkema G, Ritschel T, Voermans N, Bilos A, van Engelen B . Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015; 22(3):399-407. DOI: 10.1016/j.cmet.2015.08.002. View

18.

Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y . Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2012; 34(1):45-78. DOI: 10.1002/bdd.1823. View

19.

Knauer M, Urquhart B, Zu Schwabedissen H, Schwarz U, Lemke C, Leake B . Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2009; 106(2):297-306. DOI: 10.1161/CIRCRESAHA.109.203596. View

20.

Singhvi S, Pan H, Morrison R, Willard D . Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990; 29(2):239-43. PMC: 1380090. DOI: 10.1111/j.1365-2125.1990.tb03626.x. View